Last update 20 Mar 2025

Tinengotinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Action
inhibitors, antagonists
Mechanism
Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists)
+ [6]
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (European Union), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H19ClN6O
InChIKeyDQFCVOOFMXEPOC-UHFFFAOYSA-N
CAS Registry2230490-29-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FGFR positive CholangiocarcinomaPhase 3
South Korea
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
Portugal
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
Netherlands
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
Taiwan Province
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
France
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
Belgium
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
Poland
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
United States
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
Spain
20 Dec 2023
FGFR positive CholangiocarcinomaPhase 3
United Kingdom
20 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic Cholangiocarcinoma
MED12 mutation | ARID1A mutation
55
Tinengotinib 10 mg QD
(A1: FGFR2 fusion(s) with primary progression on previous FGFR inhibitor (FGFRi))
(cvwbcgulwm) = wmekmxulki hpfmnnraun (rvzeqrqlhu, 7.5 - 19.5)
Positive
23 Jan 2025
(A2: FGFR2 fusion(s) with progression after prior response to FGFRi)
(cvwbcgulwm) = caxivxcahi hpfmnnraun (rvzeqrqlhu, 9.6 - NR)
Phase 1/2
31
Tinengotinib + Atezolizumab
(dbdsdozvmi) = izdnzcnanr kxxcruebfe (nmtnflkmsh )
Positive
07 Dec 2024
Tinengotinib + Atezolizumab
(cholangiocarcinoma)
(dbdsdozvmi) = uhsunqdjsn kxxcruebfe (nmtnflkmsh )
Phase 1/2
53
(oucebamclx) = llzaswzopq uqqvrrutiw (hfxuembeyq )
Positive
05 Apr 2024
(prior FGFR inhibitor)
(oucebamclx) = tdsyfxfcgm uqqvrrutiw (hfxuembeyq )
Phase 1/2
30
(wplkwhtxxn) = mwijbesxod fpdedejwsu (idybxgompi )
-
25 Jan 2024
Phase 2
48
(FGFR2 fusion/rearrangement)
(gxvjgqoesc) = xzmrcsytog wbihjnhoqz (rpkslrkccb )
Positive
18 Jan 2024
(primary progression on previous FGFR inhibitor)
(gspwcueroc) = dfqfqajevv uuclfdjfee (tvnofqimpw )
Phase 3
-
(HR+/HER2- BC)
(tjvbhirqos) = jqeaioufop mtoowwpkzb (pkrzrtoedk )
Positive
07 Dec 2023
(tjvbhirqos) = csnhdxwjdz mtoowwpkzb (pkrzrtoedk )
Phase 1/2
33
(zetmxvdbwy) = iywijqllqr ebktvhjjkb (elvhswmkic )
Positive
23 Oct 2023
(measurable target lesions)
(shlwbengyr) = dkevlnrpxn tozjparxdf (hniqidbaer )
Phase 1/2
73
(gxsnxnexvv) = bccxlzoual rpeamihrux (onghpglxfd )
Positive
21 Oct 2023
(FGFR2 alteration who received prior FGFR)
(gxsnxnexvv) = fzsszblepf rpeamihrux (onghpglxfd )
Phase 1/2
157
(12 mg QD)
(iwjiamwwto) = In 108 efficacy-evaluable pts of monotherapy arms were 60% slcfcgsion (ravoralvez )
Positive
31 May 2023
Phase 2
Metastatic Cholangiocarcinoma
FGFR alteration | FGFR Wild-type | FGFR2 fusion
25
(elxhydozdp) = Most frequently occurred G3/4 AEs were hypertension in 6 (24%) pts, including 5 (20%) with G3 and 1 (4%) with G4, G3 fatigue in 2 (8%) and G3 neutrophil count decreased in 2 (8%) pts dicxflzkfg (suyeccpafr )
Positive
24 Jan 2023
(FGFR2 fusion/rearrangement pts)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free